FRANKFURT (dpa-AFX Broker) - The Evotec share price is expected to fall significantly on Wednesday. The outlook of the drug discovery company has become much more cautious, commented expert Charles Weston of the Canadian investment bank RBC.

Sales and operating profit are ultimately likely to fall well short of market expectations. There is also a question mark over the medium-term outlook. An update has been announced for this after the first half of the year. The fact that a successor was found as of July 1 following the surprising departure of Evotec's previous CEO is also being overshadowed by the outlook.

Evotec shares lost almost six percent to 13.37 euros on the Tradegate trading platform. In March, they had slipped to their lowest level for almost six years at 12.615 euros and have since been trying to bottom out./ag/mis

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------